Concord Biotech Limited has fixed Friday, July 24, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹7.55 per equity share for the financial year ended March 31, 2026. The dividend, equivalent to 755% on the face value of ₹1 each, is subject to approval by shareholders at the 41st Annual General Meeting. If approved, the payment will be made by August 30, 2026, subject to deduction of tax at source.

The company will hold its AGM on Friday, July 31, 2026, at 12:00 Noon through Video Conferencing and Other Audio-Visual Means. Pursuant to Regulation 42 of the SEBI Listing Regulations, the Register of Members and Share Transfer Books will be closed from Saturday, July 25, 2026, to Friday, July 31, 2026 (both days inclusive). The meeting agenda includes the adoption of audited financial statements for FY26 and the re-appointment of Mr. Ankur Vaid as Director.

Shareholders will also vote on the appointment of Mrs. Ekta Gupta as an Independent Director for a term of five years effective from June 01, 2026. Additionally, the company seeks approval to enhance the limit for loans, guarantees, and securities to subsidiaries, associates, and joint ventures to ₹500 Crores from the existing limit of ₹115 Crores. The ratification of remuneration for Cost Auditors, M/s. Dalwadi & Associates, at ₹3,70,000 plus applicable Goods and Services Tax for FY27 is also on the agenda.

Key Meeting Details

The Notice of AGM along with the Annual Report 2025-26 will be sent electronically to members, with physical copies available upon request. These documents will also be accessible on the company's website and the websites of BSE Limited and National Stock Exchange of India Limited.

Concord Biotech Limited has filed its Business Responsibility and Sustainability Report for the financial year 2025-26, disclosing its performance on environmental, social, and governance (ESG) parameters. The report, which forms part of the 41st Annual Report, has undergone reasonable assurance by M/s. Ramanlal G. Shah & Co., Chartered Accountants, validating the accuracy of the identified sustainability information including greenhouse gas emissions, water footprint, and employee safety metrics.

The company reported a total workforce of 2,899 individuals, comprising 1,624 employees and 1,275 workers. Women constitute approximately 7.02% of the permanent employee workforce and 2.20% of the permanent worker workforce. The median remuneration for employees other than the Board of Directors and Key Managerial Personnel was ₹600,000 per annum for males and ₹328,980 per annum for females.

Concord Biotech operates four manufacturing plants nationally and serves over 70 countries, with exports contributing 46.56% to the total turnover. The company’s primary business activities include the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs), which accounted for 78.6% of the turnover, and finished formulations, which accounted for 21.4%.

Environmental Performance

The company reported total water withdrawal of 3,88,780.1 kilolitres for FY26, with groundwater being the primary source. Water intensity per rupee of turnover stood at 0.0000368. Concord Biotech has implemented Zero Liquid Discharge (ZLD) mechanisms across all facilities, utilizing Effluent Treatment Plants (ETPs), Reverse Osmosis (RO), and Multiple Effect Evaporators (MEE) to treat and recycle wastewater.

Air emissions data indicated a rise in nitrogen oxides (NOx) to 1,65,135.23 Kg/Year from 1,42,472.60 Kg/Year in the previous year, and sulfur oxides (SOx) to 2,51,427.15 Kg/Year from 2,02,026.61 Kg/Year. The company has initiated several projects to reduce greenhouse gas emissions, including switching to natural gas for steam generation and installing energy-efficient equipment.

Governance and Assurance

The report highlights that the company received zero complaints regarding sexual harassment, forced labour, or other human rights issues during the financial year. Additionally, there were no reported instances of data breaches, product recalls, or fines imposed by regulatory bodies for non-compliance.

M/s. Ramanlal G. Shah & Co. provided reasonable assurance on the identified sustainability information, confirming that the data was prepared in all material respects in accordance with the criteria, including the Guidance Note for BRSR format. The assurance engagement excluded operations outside the defined scope and forward-looking statements.

Key Financial and Operational Metrics